↓ Skip to main content

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy

Overview of attention for article published in Clinical Gastroenterology and Hepatology, February 2004
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

patent
18 patents

Citations

dimensions_citation
49 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy
Published in
Clinical Gastroenterology and Hepatology, February 2004
DOI 10.1016/s1542-3565(03)00322-7
Pubmed ID
Authors

Rosa M Infante, Charles D Ericsson, Zhi-Dong Jiang, Shi Ke, Robert Steffen, Lise Riopel, David A Sack, Herbert L Du>Pont

Abstract

We have recently shown that enteroaggregative Escherichia coli (EAEC) strains commonly cause travelers' diarrhea. The study was designed to determine whether U.S. travelers with EAEC diarrhea responded to rifaximin therapy. In a multicenter placebo-controlled clinical trial of travelers' diarrhea without non-EAEC pathogens we evaluated 2 doses of rifaximin. EAEC was sought in stool samples in enrolled subjects by HEp-2 cell assay. Response to rifaximin (both groups combined) and placebo were evaluated in EAEC-positive and EAEC-negative patient groups. Compared with placebo, rifaximin shortened the postenrollment illness in travelers with EAEC diarrhea (median, 22 vs. 72 hours; P = 0.03). In subjects with EAEC-negative diarrhea, the median duration of post-treatment diarrhea was shorter with rifaximin (33 hours) than with placebo (52 hours), but this difference was not significantly different (P = 0.14). Improvement of EAEC-mediated diarrhea with antibiotic treatment supports the pathogenicity of this organism in travelers to developing countries. The study provides information on the value of the poorly absorbed drug rifaximin in therapy of travelers' diarrhea.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
United States 1 3%
Denmark 1 3%
Unknown 33 92%

Demographic breakdown

Readers by professional status Count As %
Other 6 17%
Student > Master 6 17%
Researcher 5 14%
Student > Ph. D. Student 4 11%
Student > Bachelor 1 3%
Other 4 11%
Unknown 10 28%
Readers by discipline Count As %
Medicine and Dentistry 10 28%
Agricultural and Biological Sciences 5 14%
Biochemistry, Genetics and Molecular Biology 1 3%
Nursing and Health Professions 1 3%
Environmental Science 1 3%
Other 4 11%
Unknown 14 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2023.
All research outputs
#3,798,945
of 25,374,917 outputs
Outputs from Clinical Gastroenterology and Hepatology
#1,611
of 4,672 outputs
Outputs of similar age
#10,201
of 146,672 outputs
Outputs of similar age from Clinical Gastroenterology and Hepatology
#2
of 14 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,672 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.9. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 146,672 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.